Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

By atthew HG Katz, P. Pisters, Douglas B. Evans, harlotte C Sun, Jeffrey E. Lee, J. Fleming, N. Vauthey, E. Abdalla, C. Crane, obert A Wolff and 2 more. Journal of the American College of Surgeons, 2008

824 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/1a743fbc576c74ed345e64c77c54e32ae540c755

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Bassi
2. J. Neoptolemos
3. C. Dervenis
4. M. Büchler
5. C. Yeo
6. H. Friess
7. K. Lillemoe
8. D. Gouma

Citations in the corpus

• International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. (2017, methodology): “This is because the anatomical definition of BR-PDAC does not take into account the biology of the tumor or the physiology of the host, both of which are determinants of resectability The approach that is presented here is derived from the ‘ABC’ method, that was developed at the MD Anderson Cancer C”
• Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial (2018, background): “A neoadjuvant approach for the treatment of BRPC or unresectable pancreatic cancer has many theoretical advantages, including early systemic treatment for undetected micrometastases, increased R0 resection rate, and reduced pancreatic leakage.(5,6) However, there are some disadvantages to this appro”
• Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). (2014, methodology): “The MDACC study group considered patient characteristics as well as anatomic parameters of the patients.(66) Patients with BRPC were categorized into three distinct groups: group A patients had BRPC with no suspicion of extrapancreatic metastatic disease; group B had suspicion of metastatic disease ”